Tim Osborne
Fortuna: 252 132 $ al 31/05/2026
Fortuna: 252 132 $ al 31/05/2026
Tim Osborne currently works at Forward Air Corp., as Executive Vice President-Operations from 2024.
Dr. Osborne also formerly worked at the University of California, Irvine, as Principal and Select BioVentures LLC, as Advisor.
Dr. Osborne received his undergraduate degree from King University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
FORWARD AIR CORPORATION 0,08 % | 15/03/2026 | 23.831 ( 0,08 % ) | 252 132 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| FORWARD AIR CORPORATION | Director de Operaciones | 01/01/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Select BioVentures LLC
Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Inversor de Capital Privado | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Forward Air Corp.
Forward Air Corp. TruckingTransportation Provides less-than-truckload, final mile, truckload and intermodal drayage services | Transportation |
King University
King University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select BioVentures LLC
Select BioVentures LLC Investment ManagersFinance Select BioVentures focuses on investments in Florida-based and other bioscience companies. The firm seeks to invest in late pre-clinical and early clinical stage private or public biopharmaceutical, medical device and molecular diagnostic companies. | Finance |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.